RNS Number : 3975L

MiLOC Group Limited

10 September 2021

10 September 2021

MiLOC GROUP LIMITED

("MiLOC" or "the Company")

NOTICE OF AGM AND ISSUED SHARES

MiLOC Group Limited (AQSE: ML.P), the AQSE Growth Market quoted pharmaceutical and healthcare group, is pleased to announce that the Annual General Meeting (the "AGM") of the Company will be held at Room 1602, 16/F Kodak House II, 39 Healthy Street East, North Point, Hong Kong on 24 September 2021 at 4:00 p.m. (Hong Kong time).

Copies of the Company's Notice of the AGM have been distributed to shareholders.  Electronic copies of the Notice of AGM as well as the Company's Annual Report and Financial Statements for the year ended 31 December 2020 are available from the Company's website www.miloc.com.

The Company notes an error in the announcement dated 4 June 2021. The actual number of Ordinary Shares in issue is 85,499,442 (not 85,449,442).

The Company announces that, following the issue of Ordinary Shares referred to in the announcement on 4^th June 2021, in accordance with the Financial Conduct Authority's Disclosure and Transparency Rules (the "Disclosure and Transparency Rules"), the total number of Ordinary Shares in issue will be 85,499,442 with each share carrying the right to one vote.

MiLOC does not hold any shares in Treasury.

The above figure of 85,499,442 ordinary shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure and Transparency Rules.

The Directors of the issuer accept responsibility for the contents of this announcement.

For further information, please contact:-

MiLOC ONG Ban Poh Michael - Chief Executive Officer    Ronnie CHOI - Chief Financial Officer	Tel: +852 2110 4221
AQSE Growth Market Corporate Adviser PETERHOUSE CORPORATE LIMITED Guy Miller Mark Anwyl	Tel: +44 (0) 20 7469 0930

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXSFDSWSEFSEDU